On September 28, 2021 Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, repoted that senior leadership plans to present at the following conferences in October (Press release, Genocea Biosciences, SEP 28, 2021, View Source [SID1234590458]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Scientific conferences:

Event: AACR: Tumor Immunology and Immunotherapy – Details
Topic: GEN-011: A neoantigen-targeted peripheral blood-derived T cell therapy that has broad neoantigen specificity and high T cell purity while avoiding pro-tumor cells
Format: Poster presentation
Date: Tuesday-Wednesday, October 5-6th
Time: Available throughout the conference

Event: Meeting on the Mesa – Details
Topic: Next-generation neoantigen-targeted solid tumor T cell therapy
Format: Presentation
Date: Tuesday-Thursday, October 12-14th
Time: Available throughout the conference

Event: CMO Summit – Details
Topic: Communicating and Pivoting After a Failed Clinical Trial
Format: Panel
Date: Friday, October 15th
Time:
1:00 p.m. ET

Event: TIL Therapies Digital Summit – Details
Topic: Identification of InhibigensTM May be the Key to Successful T cell Therapies for Solid Tumors
Format: Presentation
Date: Tuesday, October 19th
Time:
11:00 a.m. ET

Event: Neoantigen-Based Therapies Summit – Details
Topic 1: Prioritizing Diversity, Equity, and Inclusion in the Neoantigen Field
Roundtable discussion
Tuesday, October 26th
12:40 p.m. ET
Topic 2:
Responses to Inhibitory Tumor Antigens, InhibigensTM, Suppresses Anti-Tumor Immunity & promote Tumor Growth
Presentation
Wednesday, October 27th
12:30 p.m. ET
Topic 3: Unleashing the Titans: The GEN-011 Neoantigen-Targeted Peripheral T cell Therapy for Solid Tumors
Presentation
Wednesday, October 27th
5:30 p.m. ET